{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T21:02:26Z","timestamp":1771275746040,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Gansu Provincial Key R&D Program - Social Development","award":["24ZDFA006"],"award-info":[{"award-number":["24ZDFA006"]}]},{"name":"Gansu Provincial Key R&D Program - Social Development","award":["24ZDFA006"],"award-info":[{"award-number":["24ZDFA006"]}]},{"name":"Gansu Provincial Joint Research Fund - Major Projects","award":["23JRRA1501"],"award-info":[{"award-number":["23JRRA1501"]}]},{"name":"Gansu Provincial Joint Research Fund - Major Projects","award":["23JRRA1501"],"award-info":[{"award-number":["23JRRA1501"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Microbiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00203-025-04583-x","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T07:28:47Z","timestamp":1763623727000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In vitro anti-Helicobacter pylori activity and phenotypic screening of novel quinolone compounds"],"prefix":"10.1007","volume":"208","author":[{"given":"Yuan-Yuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Liang","family":"Mou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing-Lan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Xia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye-Ze","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bao-Yuan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"De-Kui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"issue":"9","key":"4583_CR1","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00203-023-03639-0","volume":"205","author":"OM Al-Fakhrany","year":"2023","unstructured":"Al-Fakhrany OM, Elekhnawy E (2023) Helicobacter pylori in the post-antibiotics era: from virulence factors to new drug targets and therapeutic agents. Arch Microbiol 205(9):301. https:\/\/doi.org\/10.1007\/s00203-023-03639-0","journal-title":"Arch Microbiol"},{"key":"4583_CR2","doi-asserted-by":"publisher","first-page":"107994","DOI":"10.1016\/j.pharmthera.2021.107994","volume":"232","author":"F Aziz","year":"2022","unstructured":"Aziz F, Khan I, Shukla S, Dey DK, Yan Q, Chakraborty A, Han YK (2022) Partners in crime: the Lewis Y antigen and fucosyltransferase IV in Helicobacter pylori-induced gastric cancer. Pharmacol Ther 232:107994. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107994","journal-title":"Pharmacol Ther"},{"key":"4583_CR3","doi-asserted-by":"publisher","unstructured":"Baj J, Forma A, Flieger W, Morawska I, Michalski A, Buszewicz G, Teresi\u0144ski G (2021) Helicobacter pylori infection and extragastric Diseases-A focus on the central nervous system. Cells 10(9). https:\/\/doi.org\/10.3390\/cells10092191","DOI":"10.3390\/cells10092191"},{"key":"4583_CR4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.atherosclerosis.2021.08.019","volume":"333","author":"J Chung","year":"2021","unstructured":"Chung J, Min KW, Son BK, Kim DH, Kim HL (2021) Association between histological severity of Helicobacter pylori infection and cardiovascular risk scores in the Korean population. Atherosclerosis 333:124\u2013130. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.08.019","journal-title":"Atherosclerosis"},{"issue":"4","key":"4583_CR5","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1021\/acsinfecdis.4c00128","volume":"10","author":"JA Collins","year":"2024","unstructured":"Collins JA, Osheroff N (2024) Gyrase and topoisomerase IV: recycling old targets for new antibacterials to combat fluoroquinolone resistance. ACS Infect Dis 10(4):1097\u20131115. https:\/\/doi.org\/10.1021\/acsinfecdis.4c00128","journal-title":"ACS Infect Dis"},{"key":"4583_CR6","doi-asserted-by":"publisher","first-page":"107247","DOI":"10.1016\/j.ejps.2025.107247","volume":"214","author":"AMK El-Sagheir","year":"2025","unstructured":"El-Sagheir AMK, Wenzel M, Yli-Kauhaluoma J (2025) Fluoroquinolones as versatile scaffolds: potential for targeting classical and novel mechanisms to combat antibacterial resistance. Eur J Pharm Sci 214:107247. https:\/\/doi.org\/10.1016\/j.ejps.2025.107247","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"4583_CR7","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00253-019-10234-1","volume":"104","author":"M Gottesmann","year":"2020","unstructured":"Gottesmann M, Paraskevopoulou V, Mohammed A, Falcone FH, Hensel A (2020) BabA and LPS inhibitors against Helicobacter pylori: pectins and pectin-like rhamnogalacturonans as adhesion blockers. Appl Microbiol Biotechnol 104(1):351\u2013363. https:\/\/doi.org\/10.1007\/s00253-019-10234-1","journal-title":"Appl Microbiol Biotechnol"},{"issue":"2","key":"4583_CR8","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1053\/j.gastro.2017.04.022","volume":"153","author":"JKY Hooi","year":"2017","unstructured":"Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, Ng SC (2017) Global prevalence of Helicobacter pylori infection: systematic review and Meta-Analysis. Gastroenterology 153(2):420\u2013429. https:\/\/doi.org\/10.1053\/j.gastro.2017.04.022","journal-title":"Gastroenterology"},{"issue":"2","key":"4583_CR9","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/1751-7915.13807","volume":"15","author":"J Jia","year":"2022","unstructured":"Jia J, Zhang C, Liu Y, Huang Y, Bai Y, Hang X, Bi H (2022) Armeniaspirol A: a novel anti-Helicobacter pylori agent. Microb Biotechnol 15(2):442\u2013454. https:\/\/doi.org\/10.1111\/1751-7915.13807","journal-title":"Microb Biotechnol"},{"key":"4583_CR10","doi-asserted-by":"publisher","unstructured":"Krzy\u017cek P, Franiczek R, Krzy\u017canowska B, \u0141aczma\u0144ski \u0141, Migda\u0142 P, Go\u015bciniak G (2019) In vitro activity of 3-Bromopyruvate, an anticancer Compound, against Antibiotic-Susceptible and Antibiotic-Resistant Helicobacter pylori strains. Cancers (Basel) 11(2). https:\/\/doi.org\/10.3390\/cancers11020229","DOI":"10.3390\/cancers11020229"},{"issue":"7","key":"4583_CR12","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1111\/jgh.14992","volume":"35","author":"JM Liou","year":"2020","unstructured":"Liou JM, Lee YC, Wu MS (2020) Treatment of Helicobacter pylori infection and its long-term impacts on gut microbiota. J Gastroenterol Hepatol 35(7):1107\u20131116. https:\/\/doi.org\/10.1111\/jgh.14992","journal-title":"J Gastroenterol Hepatol"},{"key":"4583_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327745","author":"P Malfertheiner","year":"2022","unstructured":"Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, El-Omar EM (2022) Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report. Gut. https:\/\/doi.org\/10.1136\/gutjnl-2022-327745","journal-title":"Gut"},{"issue":"Suppl 1","key":"4583_CR14","doi-asserted-by":"publisher","first-page":"e12741","DOI":"10.1111\/hel.12741","volume":"25","author":"R Pellicano","year":"2020","unstructured":"Pellicano R, Ianiro G, Fagoonee S, Settanni CR, Gasbarrini A (2020) Review: extragastric diseases and Helicobacter pylori. Helicobacter 25(Suppl 1):e12741. https:\/\/doi.org\/10.1111\/hel.12741","journal-title":"Helicobacter"},{"key":"4583_CR15","doi-asserted-by":"publisher","unstructured":"Puri S, Shalini, Juvale K, Kirubakaran S (2025) Design and development of new benzopyrazole derivatives as selective inhibitors of Helicobacter pylori IMPDH. Asian J Org Chem 9. https:\/\/doi.org\/10.1002\/ajoc.202500584","DOI":"10.1002\/ajoc.202500584"},{"issue":"28","key":"4583_CR16","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.3748\/wjg.v26.i28.4076","volume":"26","author":"MLC Santos","year":"2020","unstructured":"Santos MLC, de Brito BB, da Silva FAF, Sampaio MM, Marques HS, Oliveira ESN, de Melo FF (2020) Helicobacter pylori infection: beyond gastric manifestations. World J Gastroenterol 26(28):4076\u20134093. https:\/\/doi.org\/10.3748\/wjg.v26.i28.4076","journal-title":"World J Gastroenterol"},{"key":"4583_CR17","doi-asserted-by":"crossref","unstructured":"Shein AMS, Hongsing P, Abe S, Luk-in S, Ragupathi NKD, Wannigama DL, Chatsuwan T (2021) Will There Ever Be Cure for Chronic, Life-Changing Colistin-Resistant Klebsiella pneumoniae in Urinary Tract Infection? Frontiers in Medicine, Volume 8\u20132021","DOI":"10.3389\/fmed.2021.806849"},{"issue":"3","key":"4583_CR18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1080\/1040841x.2024.2369948","volume":"51","author":"AMS Shein","year":"2025","unstructured":"Shein AMS, Hongsing P, Smith OK, Phattharapornjaroen P, Miyanaga K, Cui L, Wannigama DL (2025) Current and novel therapies for management of acinetobacter baumannii-associated pneumonia. Crit Rev Microbiol 51(3):441\u2013462. https:\/\/doi.org\/10.1080\/1040841x.2024.2369948","journal-title":"Crit Rev Microbiol"},{"key":"4583_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(25)00438-4","author":"Z Song","year":"2025","unstructured":"Song Z, Zhou L, Wang W, Lan C, Tang T, Xie J, Ma Z (2025) Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial. Lancet Infect Dis. https:\/\/doi.org\/10.1016\/s1473-3099(25)00438-4","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"4583_CR20","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41575-021-00449-x","volume":"18","author":"E Tshibangu-Kabamba","year":"2021","unstructured":"Tshibangu-Kabamba E, Yamaoka Y (2021) Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications. Nat Rev Gastroenterol Hepatol 18(9):613\u2013629. https:\/\/doi.org\/10.1038\/s41575-021-00449-x","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"43","key":"4583_CR21","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.3748\/wjg.v30.i43.4636","volume":"30","author":"L Xie","year":"2024","unstructured":"Xie L, Liu GW, Liu YN, Li PY, Hu XN, He XY, Guo HJ (2024) Prevalence of Helicobacter pylori infection in China from 2014\u20132023: A systematic review and meta-analysis. World J Gastroenterol 30(43):4636\u20134656. https:\/\/doi.org\/10.3748\/wjg.v30.i43.4636","journal-title":"World J Gastroenterol"},{"key":"4583_CR22","doi-asserted-by":"publisher","unstructured":"Xu YF, Lian DW, Chen YQ, Cai YF, Zheng YF, Fan PL, Huang P (2017) In vitro and in vivo antibacterial activities of Patchouli Alcohol, a naturally occurring tricyclic Sesquiterpene, against Helicobacter pylori infection. Antimicrob Agents Chemother 61(6). https:\/\/doi.org\/10.1128\/aac.00122-17","DOI":"10.1128\/aac.00122-17"},{"key":"4583_CR23","unstructured":"Y Z (2023) Design, Synthesis, and Structural Optimization of Novel Antibacterial Agents Based on a 1,3-Dicarbonyl Functional Group-Oriented Strategy. Lanzhou University, Retrieved from https:\/\/link.cnki.net\/doi\/10.27204\/d.cnki.glzhu.2023.003428 Available from Cnki"},{"key":"4583_CR24","doi-asserted-by":"publisher","first-page":"114578","DOI":"10.1016\/j.jep.2021.114578","volume":"283","author":"J Yan","year":"2022","unstructured":"Yan J, Peng C, Chen P, Zhang W, Jiang C, Sang S, Yao M (2022) In-vitro anti-Helicobacter pylori activity and preliminary mechanism of action of canarium album Raeusch. Fruit extracts. J Ethnopharmacol 283:114578. https:\/\/doi.org\/10.1016\/j.jep.2021.114578","journal-title":"J Ethnopharmacol"},{"issue":"7","key":"4583_CR25","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/apt.14561","volume":"47","author":"M Zamani","year":"2018","unstructured":"Zamani M, Ebrahimtabar F, Zamani V, Miller WH, Alizadeh-Navaei R, Shokri-Shirvani J, Derakhshan MH (2018) Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther 47(7):868\u2013876. https:\/\/doi.org\/10.1111\/apt.14561","journal-title":"Aliment Pharmacol Ther"},{"issue":"01","key":"4583_CR11","first-page":"10","volume":"49","author":"JY ZHANG","year":"2018","unstructured":"ZHANG JY, e. a (2018) Research progress on Oxazolidinone-Quinolone hybrids. Acta Vet Et Zootechnica Sinica 49(01):10\u201317","journal-title":"Acta Vet Et Zootechnica Sinica"},{"issue":"9","key":"4583_CR26","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.3748\/wjg.v21.i9.2786","volume":"21","author":"YX Zhang","year":"2015","unstructured":"Zhang YX, Zhou LY, Song ZQ, Zhang JZ, He LH, Ding Y (2015) Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in beijing: a prospective serial study. World J Gastroenterol 21(9):2786\u20132792. https:\/\/doi.org\/10.3748\/wjg.v21.i9.2786","journal-title":"World J Gastroenterol"},{"issue":"6","key":"4583_CR27","doi-asserted-by":"publisher","first-page":"e12852","DOI":"10.1111\/hel.12852","volume":"26","author":"H Zhao","year":"2021","unstructured":"Zhao H, Yan P, Zhang N, Feng L, Chu X, Cui G, Yang K (2021) The recurrence rate of Helicobacter pylori in recent 10 years: A systematic review and meta-analysis. Helicobacter 26(6):e12852. https:\/\/doi.org\/10.1111\/hel.12852","journal-title":"Helicobacter"}],"container-title":["Archives of Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-025-04583-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00203-025-04583-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-025-04583-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:03:55Z","timestamp":1771272235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00203-025-04583-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4583"],"URL":"https:\/\/doi.org\/10.1007\/s00203-025-04583-x","relation":{},"ISSN":["0302-8933","1432-072X"],"issn-type":[{"value":"0302-8933","type":"print"},{"value":"1432-072X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in accordance with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Second Clinical College of Lanzhou University (ECLZUSH2023-74).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"31"}}